Thanks for posting the link, Koo.

Definitely faster than looking on their site.

Just listened quickly without even taking notes.

Nothing much new. Don't think it warrants a transcript.

List of milestones. (Can jot that part down if anyone needs, but it is right there on the slide).

Reason given for stopping Phase 2  covid trial - slow enrollment. (So not the best or worst news.)

Hinted that Phase 2 was not looking so bad data wise, but any specifics remain to be seen when or if they share results of however far they got with that data.

Expects...a next trial start or actual proof of result?  Unclear. Something in or around Mid 2023. (Shall we all mentally just add a year or two to that? Who knows?)

Still with Eversana,

Hepalink - One year extension. Honeymoon not over.

Publications we already knew about.

Interestingly no mention of recent studies re apabetalone & cocaine addiction.

Understand that they wouldn't want to be diverted to pursue it, but would think they would still be watching it and take note.

Science, regulation, & prep for commercialization strong, money not so much. 

More dual mechanism stuff. Anti-viral and anti-inflammatory.

Contractual coverage of CORAL and BETonMACE locked in.

A bunch on the challenges of  both covid & the market.

On the vote side, support for  Donald and the others still pretty high.

Probably forgetting something.

If it comes to me will add via reply.

Cheers